Bessemer Venture Partners
Listed as “Alcresta Therapeutics”
- First observed:
- 29 Oct 2026
- Investment announced:
- Date not recorded
Alcresta develops enzyme products for people receiving enteral nutrition.
Alcresta develops enzyme-based products for enterally fed patients with fat malabsorption. Its products are designed for enteral nutrition.
Some source history is available; coverage remains limited.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Listed as “Alcresta Therapeutics”
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.